Opendata, web and dolomites

USONIPRO

Ultrasonic technology for bioprocess enhancement

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "USONIPRO" data sheet

The following table provides information about the project.

Coordinator
BBH BIOTECH POLSKA SPOLKA Z OGRANICZONA OPDOWIEDZIALNOSCIA 

Organization address
address: UL. RUBIEZ 46H/250
city: POZNAN
postcode: 61 612
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Poland [PL]
 Project website http://www.bbhbiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BBH BIOTECH POLSKA SPOLKA Z OGRANICZONA OPDOWIEDZIALNOSCIA PL (POZNAN) coordinator 50˙000.00

Map

 Project objective

BBH Biotech Polska was created with a thought of using sound waves to enhance and control microbial metabolism. After 3 years of research the team created a company and focused on using sound waves as a stimulating factor in enhancing alcohol production. From the day the company was established, its strategy and long term aim was to adjust its technology of sonic fermentation enhancement to recombinant proteins, fine chemicals and drug production. The biggest problem in recombinant protein production using microbial expression systems is that a part of produced proteins are being stuck in the periplasmic space while being transported outside the cell. Treating such loaded microorganisms with adjusted sound waves can destabilize the inner membrane and outer wall in order to reclaim those proteins. This innovative procedure allows the molecules to escape the periplasmic space to the cultivation medium without destroying the cell, which was so far the biggest obstacle. Currently there are only few available methods that solve this problem, and BBH Biotech Polska is the only company developing such solution in a form of technology which is highly effective and after Phase 1 – ready to enter the market. Users of this technology will be companies producing human and animal pharmaceutical proteins with microbial expression systems. Such pharmaceuticals are expensive products, which means that an increase in production even by little, e.g. 3 – 7%, is enough to give that company an annual increase in revenue form 30 even up to 80 million dollars Our technology increases production yield from a single cultivation from 30% to 90%, depending on the protein and the expression system. Such boost to productivity will not only hasten the growth of the market, but also decrease the cost of producing e.g. insulin or platelet factors. The corresponding drugs that use them as an active compound for diabetics or patients suffering from blood clotting disorders will also cheapen.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "USONIPRO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "USONIPRO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More